Status:
COMPLETED
Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
Lead Sponsor:
Centre de Recherche en Nutrition Humaine Rhone-Alpe
Conditions:
Age Related Macular Degeneration
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
INTRODUCTION: Acting directly on the anti-radical enzyme chain, the superoxide dismutase (SOD), a major enzyme of the anti-oxidant system, provides an alternative of the antioxidants treatment in ARM...
Eligibility Criteria
Inclusion
- unilateral neo-vascular ARMD
Exclusion
- other pathology
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00800995
Start Date
September 1 2005
End Date
June 1 2008
Last Update
December 3 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire de Grenoble
Grenoble, France, 38043